share_log

Silence Therapeutics Seeks Approval to Cancel AIM Trading

Dow Jones Newswires ·  Oct 15, 2021 02:40

By Ian Walker

Silence Therapeutics PLC said Friday that it is seeking shareholder approval to cancel its listing on London's junior AIM, keeping a single listing on New York's Nasdaq.

The medical company said delisting from AIM will enhance liquidity in its American Depositary Shares and increase U.S. investors' willingness to invest in the company.

If approved by shareholders at a general meeting on Nov. 1, the last trading day on AIM is expected to be Nov. 29, it said.

Write to Ian Walker at ian.walker@wsj.com

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment